Restoration Biosciences

Restoration Biologics is a private U.S. regenerative medicine and musculoskeletal R&D company focused on restoring joint and cartilage function. The company develops scientific approaches spanning cartilage repair, tissue engineering, regenerative medicine, and medical devices, and it partners with commercial and academic groups to translate these technologies toward orthopedic applications. In February 2025, Restoration Biologics entered exclusive global licensing agreements with Akos Biosciences, a subsidiary of Enveric Biosciences, covering cannabinoid-COX-2 conjugate compounds for pharmaceutical and non-pharmaceutical uses in joint disease. Its near-term focus appears to include osteoarthritis, rheumatoid arthritis, cartilage repair, and broader bone and joint pathologies.